Relapse in the skull after myeloablative therapy for high-risk neuroblastoma

D. Sangthawan, P. M. DesRosiers, M. E. Randall, K. Robertson, S. Goebel, R. Fallon

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Patterns of relapse were determined for 20 high-risk neuroblastoma patients treated with chemotherapy, surgery, primary and metastatic site radiation (21 Gray), myeloablative chemotherapy, peripheral blood stem cell rescue, and 13-cis-retinoic acid. The median follow-up duration after transplant is 21 months (range, 8-34 months). The event-free survival and overall survival at 2 years were 45 and 75 %, respectively. There were 2 primary site recurrences. Metastatic sites that became MIBG-scan negative on induction chemotherapy were not irradiated. Four patients relapsed in irradiated metastatic sites, 3 in the skull, 1 in the liver. Failure also occurred at 2 skull sites treated with chemotherapy only, and at 5 new sites: 1 skull, 2 distant lymph nodes, and 2 bones other than skull. Eight of 20 patients had skull metastasis at presentation; 6 were irradiated and 3 were controlled. Skull metastasis warrants more aggressive evaluation and treatment.

Original languageEnglish (US)
Pages (from-to)23-30
Number of pages8
JournalPediatric Hematology and Oncology
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2003

    Fingerprint

Keywords

  • Neuroblastoma
  • Radiation
  • Stem cell transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation

Cite this